Intelligence Feed event · Macro · 2026-09-24

    Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs

    Question

    Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs

    Direct answer

    Ionis Pharmaceuticals reported successful Phase III clinical outcomes across two late-stage pipeline programs, validating its antisense platform in distinct rare disease indications. The FUSION trial for ulefnersen in FUS-ALS reached its primary objective with Otsuka handling regulatory submission, while the IMAgINATION trial for sefaxersen in IgA nephropathy confirmed statistically meaningful proteinuria reduction.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/ionis-announces-positive-phase-iii-results-for-partnered-fus-als-and-igan-progra-64f458

    MACRO
    Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs
    Ionis Pharmaceuticals reported successful Phase III clinical outcomes across two late-stage pipeline programs, validating its antisense platform in distinct rare disease indications. The FUSION trial for ulefnersen in FUS-ALS reached its primary objective with Otsuka handling regulatory submission, while the IMAgINATION trial for sefaxersen in IgA nephropathy confirmed statistically meaningful proteinuria reduction.
    IONS
    Impact
    70
    SEP 24
    SIG
    88%
    IONS
    Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs
    Ionis Pharmaceuticals reported successful Phase III clinical outcomes across two late-stage pipeline programs, validating its antisense platform in distinct rare disease indications. The FUSION trial for ulefnersen in FUS-ALS reached its primary objective with Otsuka handling regulatory submission, while the IMAgINATION trial for sefaxersen in IgA nephropathy confirmed statistically meaningful proteinuria reduction.
    → Positive Phase III readout data clears regulatory path toward commercial royalty streams and partner milestone recognition.
    Impact
    Ionis Pharmaceuticals reported successful Phase III clinical outcomes across two late-stage pipeline programs, validating its antisense platform in distinct rare disease indications. The FUSION trial for ulefnersen in FUS-ALS reached its primary objective with Otsuka handling regulatory submission, while the IMAgINATION trial for sefaxersen in IgA nephropathy confirmed statistically meaningful proteinuria reduction.
    Affected
    IONS
    Transmission
    Positive Phase III readout data clears regulatory path toward commercial royalty streams and partner milestone recognition.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    IONSbiotech pipeline derisking and future commercial royalty realizationUp1-4wPositive Phase III FUSION and IMAgINATION data met primary endpoints.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    IONSUpagreed43.81 2026-09-24+1.57%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month